Division of Developmental Medicine, Boston Children's Hospital, Boston, MA 02115.
Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115.
Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2300052120. doi: 10.1073/pnas.2300052120. Epub 2023 May 30.
Short trinucleotide expansions at the FMR1 locus are associated with the late-onset condition fragile X-associated tremor/ataxia syndrome (FXTAS), which shows very different clinical and pathological features from fragile X syndrome (associated with longer expansions), with no clear molecular explanation for these marked differences. One prevailing theory posits that the shorter, premutation expansion uniquely causes extreme neurotoxic increases in FMR1 mRNA (i.e., four to eightfold increases), but evidence to support this hypothesis is largely derived from analysis of peripheral blood. We applied single-nucleus RNA sequencing to postmortem frontal cortex and cerebellum from 7 individuals with premutation and matched controls (n = 6) to assess cell type-specific molecular neuropathology. We found only modest upregulation (~1.3-fold) of FMR1 in some glial populations associated with premutation expansions. In premutation cases, we also identified decreased astrocyte proportions in the cortex. Differential expression and gene ontology analysis demonstrated altered neuroregulatory roles of glia. Using network analyses, we identified cell type-specific and region-specific patterns of FMR1 protein target gene dysregulation unique to premutation cases, with notable network dysregulation in the cortical oligodendrocyte lineage. We used pseudotime trajectory analysis to determine how oligodendrocyte development was altered and identified differences in early gene expression in oligodendrocyte trajectories in premutation cases specifically, implicating early cortical glial developmental perturbations. These findings challenge dogma regarding extremely elevated increases in FXTAS and implicate glial dysregulation as a critical facet of premutation pathophysiology, representing potential unique therapeutic targets directly derived from the human condition.
在 FMR1 基因座上的短三核苷酸扩展与晚发性脆性 X 相关震颤/共济失调综合征 (FXTAS) 相关,与脆性 X 综合征(与更长的扩展相关)相比,它表现出非常不同的临床和病理特征,对于这些明显的差异没有明确的分子解释。一种流行的理论假设是,较短的、前突变扩展独特地导致 FMR1 mRNA 的极度神经毒性增加(即增加四到八倍),但支持这一假设的证据主要来自对外周血的分析。我们应用单细胞 RNA 测序技术对 7 名前突变个体和匹配对照者(n = 6)的死后额皮质和小脑进行了研究,以评估细胞类型特异性的分子神经病理学。我们仅在前突变扩展相关的一些神经胶质群体中发现 FMR1 的适度上调(~1.3 倍)。在前突变病例中,我们还发现皮质中的星形胶质细胞比例降低。差异表达和基因本体分析表明,神经胶质的神经调节作用发生改变。通过网络分析,我们确定了前突变病例中独特的、与 FMR1 蛋白靶基因失调相关的细胞类型特异性和区域特异性模式,皮质少突胶质细胞谱系中的网络失调尤为明显。我们使用拟时间轨迹分析来确定少突胶质细胞发育是如何改变的,并确定了前突变病例中少突胶质细胞轨迹中早期基因表达的差异,这特别涉及到早期皮质神经胶质发育的扰动。这些发现挑战了关于 FXTAS 中极度升高的增加的教条,并暗示神经胶质失调是前突变病理生理学的一个关键方面,代表了直接源自人类疾病的潜在独特治疗靶点。